BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Sanofi's Toujeo® (insulin glargine 300 Units/mL) Max SoloStar®, the highest capacity long-acting ...

Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up ...

Sanofi (Euronext: SAN; NYSE: SNY) announced today that it received FDA approval for its Toujeo Max SoloStar insulin pen, the highest capacity long-acting insulin pen that will be available on the ...

The FDA approved a 900-unit insulin glargine pen, the highest capacity long-acting insulin pen on the market in the U.S., Sanofi announced in a press release. The new insulin glargine (Toujeo) Max ...

PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine product on the ...

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus. The Food and Drug Administration ...

Paris, France - February 27, 2015 - Sanofi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion ...

A longer-acting version of the world's best-selling diabetes drug is now available in the U.K. Sanofi ($SNY) announced the availability of the long-acting basal ...

In Photo: Prof. Helen Baron of The Keck School of Medicine in California discusses Type 2 Diabetes Mellitus: Perspectives on Current Insulin Therapy. Health-care company Sanofi-Aventis has announced ...